Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 0.43 |
| ▸ | HTR2A | P28223 | 15/20 | 0.43 |
| ▸ | HTR2B | P41595 | 14/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL224424 | 0.99 | HTR2C (0.42) | HTR2CHTR2AHTR2BCYP3A4TACR1 | |
| Hydrochloric Acid SCHEMBL2849333 | 0.80 | HTR2C (0.40) | HTR2CHTR2AHTR2BTACR1 | |
| SCHEMBL2337017 | 0.75 | DPP4 (0.40) | HTR2CHTR2AHTR2B | |
| SCHEMBL29138915 | 0.73 | HTR2C (0.43) | HTR2CHTR2AHTR2B | |
| SCHEMBL2336871 | 0.73 | RIPK1 (0.40) | HTR2CHTR2AHTR2B | |
| SCHEMBL29138927 | 0.73 | HTR2C (0.43) | HTR2CHTR2AHTR2B | |
| SCHEMBL29138924 | 0.73 | HTR2C (0.43) | HTR2CHTR2AHTR2B | |
| SCHEMBL4430758 | 0.71 | HTR2C (0.50) | HTR2CHTR2AHTR2B | |
| SCHEMBL27864766 | 0.71 | HTR2C (0.51) | HTR2CHTR2AHTR2B | |
| SCHEMBL27847783 | 0.71 | HTR2C (0.51) | HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1827438-B2 | PIPERAZIN DERIVATIVES FOR INHIBITING HUMAN STEAROYL-COA-DESATURASE | XENON PHARMACEUTICALS INC (CA) | 2014-12-10 | — | — | EP | disclosed |
| EP-1651606-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-10-24 | — | — | EP | disclosed |
| US-8153636-B2 | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-04-10 | — | — | US | disclosed |
| EP-2316457-A1 | Pyridine derivatives for inhibiting human stearoyl-coa-desaturase | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| EP-2316825-A1 | Pyridyl derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| EP-1827438-B1 | PYRIDINE DERIVATIVES FOR INHIBITING HUMAN STEAROYL-COA-DESATURASE | XENON PHARMACEUTICALS INC (CA) | 2011-01-12 | — | — | EP | disclosed |
| US-7759348-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-07-20 | — | — | US | disclosed |
| US-7754711-B2 | Antidiabetic agents; disease of glucose tolerance; insulin resistance; obesity; dyslipidemia; metabolic disorders; liver disorders | XENON PHARMACEUTICALS INC. (CA) | 2010-07-13 | — | — | US | disclosed |
| US-20100048584-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-02-25 | — | — | US | disclosed |
| US-7605161-B2 | 1-Pentyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}urea; inhibitors of stearoyl-CoA desaturase; cardiovascular disease, diabetes, obesity, metabolic syndrome | XENON PHARMACEUTICALS INC. (CA) | 2009-10-20 | — | — | US | disclosed |
| US-20080167321-A1 | Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase | XENON PHARMACEUTICALS INC. (CA) | 2008-07-10 | — | — | US | disclosed |
| EP-1827438-A2 | PYRIDINE DERIVATIVES FOR INHIBITING HUMAN STEAROYL-COA-DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2007-09-05 | — | — | EP | disclosed |
| US-20060199802-A1 | Pyridyl derivatives and their use as therapeutic agents | DISCOVERY PARTNERS INTERNATIONAL, INC. | 2006-09-07 | — | — | US | disclosed |
| EP-1651606-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | disclosed |
| WO-2006034446-A2 | PYRIDINE DERIVATIVES FOR INHIBITING HUMAN STEAROYL-COA-DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005011656-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048584-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | PRMT9, SNRPD3, SCD | HTR2C 4259/4885HTR2A 1676/4885HTR2B 2212/4885 |
| US-20080167321-A1 | Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase | SCD, SCD5, FADS2 | HTR2C 4448/4885HTR2A 3095/4885HTR2B 3761/4885 |
| US-20060199802-A1 | Pyridyl derivatives and their use as therapeutic agents | PYCR1, PNPO, UQCRC1 | HTR2C 2955/4885HTR2A 1410/4885HTR2B 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.